RedHill Biopharma
Kukbo acquired the shares of US/Israeli Biotechnology company RedHill Biopharma and therefore gained the right of first negotiation on the copyright contract to distribute oral Covid-19 medicines within Korea and throughout Asia.
Products
Kukbo plans to sell RHB-107(Upamostat), Opaganib, Talicia®, 3 in total, and expects to be a Game Changer in the healthcare market by playing a significant role in the ending of the Covid-19 pandemic through its local expertise and network.
TaliciaⓇ
This is a fixed-dosage, oral complex made up of amoxicillin, rifabutin, PPI and omeprazole and is
for the treatment of Helicobacter pylori found inside an adult’s stomach. Talicia is the only rifabutin-based drug that does not show any tolerance to rifabutin, one of the main ingredients of Talicia.
RHB-105(Opaganib)
It is a potential tier 1 inhibitor of the Trypsin-like serine protease type which can be used for the
treatment of cancer, inflammatory lung disease, irritable bowel syndrome, inflammatory intestinal disease and pancreatitis. It is administered orally and is used to treat mild cases of Covid-19.
RHB-107(Upamostat)
An orally-administered sphingosine kinase-2 inhibitor including ongoing anti-cancer and anti-
inflammation activities having different types of oncology, inflammation, the GI as targets.
This is a drug for severe cases of Covid-19 which minimizes the risk of tolerance due to a mutated variant of a virus caused by strong antiviral activities targeting important host factors.
